Norepinephrine (NE) and serotonin has been postulated to play an important role in the pathophysiology and subsequent treatment of depression. There is a considerable amount of evidence to support a pivotal role for norepinephrine in the brain, both as a neurotransmitter and as a modulator of other central nervous system (CNS) neurotransmitters, and CNS norepinephrinergic neurotransmission appears to have a major impact on the symptomatology in major depressive disorder (MDD).
1) The norepinephrine transporter (NET) reaccumulates and recycles released norepinephrine into presynaptic terminals, 2) and blockade of NET has been reported to be concerned with efficacy of tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors (SNRIs). [3] [4] [5] These findings suggest that the NET gene polymorphisms have a possibility to be involved in susceptibility to MDD as well as in individual difference of antidepressant response. The authors reported that the C/C genotype of the NET T-182C polymorphism was associated with lesser susceptibility to MDD.
6) The NET T-182C polymorphism may be in part related to the pathophysiology of major depressive disorder in a Japanese population.
Another NET gene polymorphism of G1287A (rs5569) in exon 9 has been reported, 7) and its implication in several psychiatric disorders has been investigated in Caucasian populations. [8] [9] [10] However, its involvement in susceptibility to MDD has not yet investigated in Oriental populations. In the present study, the authors investigated whether the NET G1287A polymorphism is associated with the susceptibility to MDD first in a Japanese population.
MATERIALS AND METHODS

Subjects
This study included 164 healthy volunteers (101 male, 63 female) and 145 patients with major depressive disorder (55 male, 90 female). The mean age (ϮS.D.) of the major depressive patients was 51.6Ϯ12.4 years and that of healthy volunteers was 55.2Ϯ16.4 years. Japanese patients who fulfilled the DSM-IV diagnosis of major depressive disorder and who exhibited Montgomery and Åsberg Depression Rating Scale (MADRS) scores 11) of Ն21 were included in this study. Patients with other Axis I or Axis II disorders were excluded by careful clinical interview, and those with severe medical disorders were also excluded. Healthy nonrelated subjects were screened with the use of a questionnaire and subjects without any history of psychiatric disorders and previous psychiatric treatment were included in this study. This study was approved by the ethics committee of Akita University School of Medicine, and all patients and healthy volunteers provided a written informed consent.
Method of Genotyping Leukocyte genomic DNA was extracted directly from the blood specimen using a QIAamp blood Mini Kit (QIAGEN, Tokyo, Japan). The NET G1287A polymorphism was determined by PCR restriction fragment length polymorphism (PCR-RFLP) as reported by Jonsson et al. 12) Briefly, samples (20 ml) were of a PCR mixture containing 100 ng of genomic DNA template, 2.0 mM MgCl 2 , each 0.5 mmol of forward primer (5Ј-TTC AGG GAG ACC CTA ATT CC-3Ј) and reverse primer (5Ј-TTG ACT TTA TTG AAA TGC GGC-3Ј), 200 mM of dNTP mixture and 1.25 units of HotStar Taq DNA polymerase (QIAGEN, Tokyo, Japan). Amplification was performed by GeneAmp PCR sys- Norepinephrinergic neurotransmission in the central nervous system have a major impact on the symptomatology in major depressive disorder (MDD), and genetic polymorphisms of norepinephrine transporter (NET) have a possibility to be involved in susceptibility to MDD. We investigated the association of the G1287A (rs5569) polymorphism of the NET gene and susceptibility to MDD by comparing 145 major depressive patients with 164 healthy individuals first in a Japanese population. The genotype frequencies in depressed patients and health volunteers of the NET G1287A polymorphism were 52.4% (G/G), 39.3% (G/A) and 8.3% (A/A) in depressed patients, 61.6% (G/G), 29.9% (G/A allele) and 8.5% (A/A) in healthy volunteers, respectively. The allele frequencies in depressed patients and health volunteers of the NET G1287A polymorphism were 72.1% (G allele) and 27.9% (A allele) in depressed patients, 76.5% (G allele) and 23.5% (A allele) in healthy volunteers, respectively. The genotype distribution and allele frequencies were not significantly different between major depressive patients and healthy volunteers. NET G1287A polymorphism appears not to be an important factor in susceptibility to MDD in a Japanese population.
tem 2400 (Perkin-Elmer, Norwalk, CT). PCR conditions were initial denaturation step of 15 min 95°C, 35 cycles of 30 s at 95°C; 30 s at 53°C; 30 s 72°C, and final extension step of 10 min at 72°C. The amplified PCR product (241 bp) was digested with 10 units of Sau96 I (New England BioLab, Beverly, MA, U.S.A.) for 3 h at 37°C. Digested products were electrophoresed on 10% polyacrylamide gel and then stained with ethidium bromide. Genotype was determined by digestion pattern of PCR products by Sau96 I (wild G allele: 21ϩ76ϩ31ϩ113 bp, mutant A allele: 97ϩ31ϩ113 bp).
Statistical Analysis The Chi-Square test was utilized for comparisons of the genotype distribution and allele frequencies between healthy volunteers and major depressive patients. Power analysis was performed with the use of G.Power (computer software). Table 1 shows genotype distribution and allele frequencies in major depressive patients and healthy volunteers. There was no significant difference in the genotype distribution and allele frequencies between major depressive patients and healthy volunteers. These results suggest that the NET G1287A polymorphism is not associated with susceptibility to MDD.
13) RESULTS
Genotype Distribution and Allele Frequencies of NET
G1287A Polymorphism in a Japanese Population
Power This study had a power of 0.33 to detect a small effect, 0.99 to detect a medium effect and 0.99 to detect a large effect in the genotype distribution (nϭ309). In the allele frequencies (nϭ618), this study had a power of 0.70 to detect a small effect, 0.99 to detect a medium effect and 0.99 to detect a large effect. In this power analysis, effect size conventions were determined according to Buchner et al. 13) as follows: small effect sizeϭ0.10, medium effect sizeϭ0.30, large effect sizeϭ0.50, alphaϭ0.05.
DISCUSSION
The present study revealed that the NET G1287A polymorphism might not play a major role in susceptibility to MDD first in a Japanese population.
Several investigators have reported the relationship between the NET G1287A polymorphism and several psychiatric disorders including MDD, 7, 14, 15) schizophrenia, 8) alcohol dependence 10) and panic disorder 16) in Caucasian and Han Chinese populations, and none of them showed significant relationship. The present results replicated those by Owen et al., 7) Zill et al., 14) and Chang et al. 15) in a Japanese population. The frequency of G/G genotype in patients with MDD was about 10% lower than that in healthy volunteers in this study though the statistical difference was not significant.
The relationship of G/G genotype and the resistance to MDD may be expected. This may be proved by clinical study using increased number of subjects.
The ethnic difference in NET T-182C polymorphism and the susceptibility to MDD has been reported. The C/C genotype was associated with lesser susceptibility to MDD in Japanese popultion.
6) The T/T genotype was associated with the lesser susceptibility to MDD in Korean population. 17) There is no association between any genotype and MDD in Caucasian populations 14) and Han Chinese. 15) As for NET G1287A polymorphism, the A allele frequency in Japanese healthy volunteers (23.5%) reported in this study was lower than that in previously reported Caucasian (33.1-33.5%), 7, 14) and Han Chinese (35.7%) populations. 15) Although the large scale study should be done for confirmation, the A allele frequency of NET G1287A polymorphism may account for the ethnic difference in the susceptibility to MDD as well as NET T-182C polymorphism.
Stober et al. reported that the NET G1287A polymorphism was a silent mutation.
18) The negative findings of our own and previous studies might be explained by the synonymity of the NET G1287A polymorphism. However, Jonsson et al. reported that this polymorphism was associated with the cerebrospinal fluid (CSF) concentration of 3-methoxy-4-hydroxyphenylglycol (MHPG), a major norepinephrine metabolite. 12) They reported that the CSF MHPG concentrations were higher in the G/G genotype than in the G/A and A/A genotypes in healthy volunteers. Hirose et al. reported that the urinary concentration of D-MHPG in depressive patients was 1.3 times higher than that in healthy volunteers. 19) We have reported that the A/A genotype is associated with a slower response of milnacipran than G/A genotype in Japanese major depressed patients. 20) Kim et al. reported that G/G genotype in this polymorphism is associated with better response to the norepinephrine reuptake inhibitors (NRIs) than to selective serotonin reuptake inhibitors (SSRIs). 21 ) From these observations, NET G1287A polymorphism may also be useful for predicting the response to NET-directed antidepressant.
In conclusion, we did not find the positive correlation between the NET G1287A polymorphism and the susceptibility to MDD in Japanese population. However we got the positive but not significant findings in this study. For re-evaluation of NET G1287A polymorphism as a predictive marker for the susceptibility to MDD in Japanese population and other ethnic groups, we are planning to perform the large-scale study using increased number of subjects. 
